How Compounded Semaglutide Is Made: From Prescription to Vial

The Quick Answer

Legitimate compounded semaglutide is made in five traceable steps: a licensed prescriber writes a patient-specific prescription; a state-licensed 503A pharmacy sources pharmaceutical-grade semaglutide from an FDA-registered supplier with a certificate of analysis; pharmacists prepare the sterile injection inside an ISO-classified cleanroom under USP Chapter <797> standards; the batch is assigned a beyond-use date and tested for potency and sterility; and the finished vial ships in cold-chain packaging held at 2 to 8 degrees Celsius. Every legitimate vial can be traced to a licensed prescriber, a licensed pharmacy, and a tested batch. If any of those three links is missing, the product is not compounded medicine. It is an unregulated chemical.

That distinction matters more in 2026 than ever, because the market now contains both: pharmacies doing careful, inspected sterile work, and online sellers shipping "research use only" powder with none of it. This article walks through each step, what the standards require, and the red flags that separate a real 503A preparation from a grey-market product. For the regulatory backdrop, see our 2026 update on FDA compounding rules.

Step 1: A Patient-Specific Prescription

Everything in legitimate compounding starts with a prescription written for one named patient. Per section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare a medication only in response to a valid prescription from a licensed prescriber for an identified individual patient. The pharmacy cannot legally manufacture a stockpile of semaglutide and sell it to whoever clicks a buy button. The prescription is the legal trigger for the entire process.

In a telehealth model, that prescription follows a clinical evaluation. At Trimi, a licensed provider reviews your health history, medications, and goals, and decides whether treatment is appropriate for you at all. Not everyone is approved. If a GLP-1 is appropriate, the provider writes a prescription for compounded semaglutide or compounded tirzepatide at a specific dose, and that prescription, tied to your name, is transmitted to the pharmacy. You can see the full sequence on our how it works page.

This is also the clearest dividing line from the grey market. A website that sells "semaglutide" with no prescriber evaluation and no prescription is not compounding under 503A; it is selling an unapproved drug outside the regulated pharmacy system.

Step 2: Sourcing Pharmaceutical-Grade Semaglutide

A compounding pharmacy does not synthesize semaglutide itself. It purchases the active pharmaceutical ingredient, or API, from a specialized supplier. Section 503A sets conditions on that purchase: the bulk drug substance must be manufactured in an establishment registered with FDA, and it must be accompanied by a valid certificate of analysis documenting its identity and purity. The pharmacy keeps that paperwork, and state inspectors can ask for it.

The form of the ingredient matters. FDA has specifically cautioned that some sellers use salt forms of semaglutide, such as semaglutide sodium and semaglutide acetate, which are different substances from the base semaglutide used in the FDA-approved products. A careful pharmacy sources the base form and can show documentation proving it. A grey-market seller often cannot tell you which form it ships, and "research grade" peptide vendors typically operate with no FDA registration at all.

This is the least visible step in the chain and one of the most important. Two vials can look identical; the difference lives in the supplier's registration status, the certificate of analysis, and the identity testing the pharmacy performs on arrival. Sourcing documentation is one of the first things we examine in our guide to the best compounded GLP-1 providers.

Step 3: Sterile Compounding Under USP <797>

Semaglutide is injected, so it must be prepared as a sterile product. The national standard for that work is USP General Chapter <797>, published by the United States Pharmacopeia and enforced by state boards of pharmacy. It dictates the physical environment, the people, and the process.

The environment is an ISO-classified cleanroom suite. The actual compounding happens inside an ISO Class 5 primary engineering control, typically a laminar airflow hood or isolator. Per the ISO 14644-1 standard, ISO Class 5 air contains no more than 3,520 particles of 0.5 microns or larger per cubic meter, which is dramatically cleaner than ordinary indoor air. That hood sits inside an ISO Class 7 buffer room, entered through an ISO Class 8 ante room where staff wash and garb. Pressure, temperature, humidity, and surface contamination are monitored on a defined schedule.

The people are tested, not just trained. USP <797> requires compounding personnel to pass gloved fingertip sampling and media-fill tests, simulated compounding runs using a growth medium that turns visibly positive if their technique introduces microbes. Fail, and they do not compound until they requalify.

The process is aseptic technique: sterilized components, disinfected surfaces, first-air positioning inside the hood, and filtration or terminal sterilization of the finished preparation. None of this exists in a grey-market operation filling vials in an office. Sterility failures in injectables are not cosmetic defects; contaminated injections can cause serious infections, which is why the standard is this demanding.

Step 4: Beyond-Use Dating and Batch Testing

A compounded preparation does not get a manufacturer-style expiration date. It gets a beyond-use date, or BUD, assigned under USP <797> based on how it was made, how it is stored, and whether it passed sterility testing. Under the current standard, an aseptically processed Category 2 preparation that passes sterility testing may be assigned a BUD of up to 45 days when refrigerated. Shorter-dated categories exist for preparations made under less controlled conditions. The BUD is printed on the label, and using the medication past it is not recommended.

Quality-focused pharmacies also test the batch itself. Sterility testing follows USP <71>, bacterial endotoxin testing follows USP <85>, and potency testing confirms the vial contains the labeled amount of semaglutide. Many 503A pharmacies send these samples to independent third-party laboratories, which removes the conflict of interest of a pharmacy grading its own work. Trimi's partner pharmacies, VialsRx (Texas State Board of Pharmacy license #35264) and GreenwichRx, operate as state-licensed 503A sterile compounding pharmacies within this testing framework.

Testing verifies identity, potency, sterility, and endotoxin levels for that lot. It does not make a compounded preparation FDA-approved, and it does not substitute for clinical trials. In the STEP 1 trial published in the New England Journal of Medicine in 2021, adults taking semaglutide 2.4 mg lost an average of 14.9 percent of body weight over 68 weeks versus 2.4 percent with placebo; in the SURMOUNT-1 trial, tirzepatide at the highest dose produced an average 20.9 percent reduction over 72 weeks. Those results come from the FDA-approved products, and the efficacy of compounded preparations has not been established in clinical trials. Individual results vary. For a deeper treatment of this evidence question, read our analysis of whether compounded semaglutide is safe in 2026.

Step 5: Cold-Chain Packaging and Shipping

Semaglutide is a peptide, and peptides degrade with heat. Per FDA prescribing information for approved semaglutide products, unopened pens are stored refrigerated at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit), and compounded semaglutide follows the same cold-storage logic. The last mile is therefore part of the quality system, not an afterthought.

Legitimate pharmacies ship in insulated containers with gel packs or phase-change materials sized to hold that range for the full transit window, and they favor fast transit. This is why Trimi ships free overnight once your prescription is compounded: shorter transit, smaller excursion risk. When your vial arrives, it goes straight into your refrigerator, and the label carries the beyond-use date and storage instructions.

A seller that ships peptide vials in a padded envelope with no thermal protection is telling you, in packaging form, that no pharmacist reviewed its process.

Legitimate 503A vs. Grey-Market "Research Chemicals"

Put the whole chain together and the contrast with the grey market becomes stark. A legitimate preparation has a prescriber, a pharmacy license you can verify, documented API sourcing, a cleanroom, a beyond-use date, and batch testing. A grey-market product, often labeled "for research use only" to dodge drug regulation, has none of these. Here are the specific red flags:

Price is the honest tension here. Grey-market vials are cheap precisely because every safeguard has been stripped out. The regulated alternative costs more, but less than many people assume: our roundup of the cheapest legal GLP-1 options online in 2026 maps the realistic price floor for care that still includes a prescriber, a licensed pharmacy, and tested medication. Prefer a brand product? Our LillyDirect Zepbound pricing guide explains how the manufacturer's direct channel works.

Frequently Asked Questions